EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngealcancer at ESMO IO 2024 Paris, France, 9 December 2024 – EnnoDC, a clinical-stage biotech company ...
Some results have been hidden because they may be inaccessible to you